Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: A phase II single institution trial

M. P. Devetten, M. H. Qazilbash, C. L. Beall, P. Bunner, R. Weisenborn, J. P. Lynch, S. G. Ericson

Research output: Contribution to journalArticle

7 Scopus citations


Relapse of hematologic malignancies after allogeneic stem cell transplantation remains a common problem, in particular for patients who have advanced disease at the time of transplantation. Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms. We retrospectively analyzed toxicity, engraftment and survival data of 41 patients who received a conditioning regimen of thiotepa (600 mg/m2) and hyperfractionated TBI (10 Gy) prior to matched related (n = 25) or matched unrelated (n = 16) allogeneic stem cell transplantation. The mean age at transplantation was 37.8 years (range 20-59), all but five patients had advanced hematologic malignancies at the time of transplantation. GVHD prophylaxis was with standard cyclosporine and methotrexate. Engraftment was excellent, but the regimen was associated with a high incidence of grade III renal (41%) and hepatic (15%) toxicity, and high transplant-related mortality (44% at day + 90). The 3-year event-free survival was 13% and overall survival 14%. We conclude that this regimen requires modification to reduce toxicity.

Original languageEnglish (US)
Pages (from-to)577-580
Number of pages4
JournalBone marrow transplantation
Issue number7
StatePublished - Oct 1 2004



  • TBI
  • Thiotepa
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this